Dr. Jan Wasley - SAB Chairman
Dr Jan Wasley's scientific background lies in organic and medicinal chemistry. He received his B.Sc. degree in chemistry in 1959 and his Ph.D. (synthesis of pyrroles, porphyrins and related macrocycles) in 1962 from Professor A.W. Johnson at the University of Nottingham, England. Following a postdoctoral fellowship (1962-1964) at the National Research Council of Canada, Dr. Wasley joined the Research Division of Geigy Pharmaceuticals in 1965 as a Senior Chemist, gradually holding positions of increasing responsibility within the Research Department at Ciba-Geigy drug discovery and drug development activities as Executive Director Research Support. Most recently he was responsible for identifying new technologies, Strategic Planning and managing external collaborations. In 1993 Dr. Wasley joined Neurogen Corporation as Director of Chemistry and in 1995 took on the added responsibility of VP Business Development where he became involved in the development of Neurogen's Accelerated Intelligent Drug Design (AIDD) technologies. He retired from Neurogen in August 2001 and formed SimPharma LLC and has established an international client base over the past 11 years. In addition, Dr. Wasley was appointed to the position of Chief Scientific Officer at the Institutes for Pharmaceutical Discovery, having joined the Affiliated Institute of Bioanalytics in 2001as Director before taking on the additional role of CSO of all the Institutes the following year. Dr. Wasley has more than 45 years experience in the design, discovery and development of novel drugs for a wide variety of diseases and has over 100 publications and patents in the area of medicinal chemistry. During that time he discovered/developed more than 25 drugs that reached advanced clinical or preclinical status. He has taught and lectured on drug design, discovery and development at the University of Connecticut and Wesleyan University and is a WWBoard Member for the Society of Concurrent Product Development. He has more than 90 publications and patents in the field of medicinal chemistry.
Dr. Karim Berrada - SAB Co-Chairman
Dr. Karim Berrada received his M.Sc. degree at Cleveland State University where he studied water-born human parasites. For his Ph.D., he joined the Cancer Biology Department of the Lerner Research Center at the Cleveland Clinic Foundation, at which he studied leukemogenesis. After completing a three year fellowship at the Clinical & Molecular Endocrinology of Case Western Reserve University/University Hospital of Cleveland, he joined the private sector where he held key positions and focused on the early phases of drug discovery. Dr. Berrada has served as Principal Investigator at Athersys, Synaptic and Helicon Therapeutics, and in 2003, he joined Ingenious Targeting Laboratories where he established a drug discovery program while managing also the development of various leads. Since 2012, he joined Applied DNA Sciences as a Director of DNA formulation department.
Prof. Jean-Francois Rossi
Jean-Francois Rossi is Professor of Hematology at the University Montpellier I, in the Department of Clinical Hematology of Montpellier CHRU, and also co-director of the Immune Therapy Program in the INSERM U1040 (Institute for Research in Biotherapy, Montpellier) in association with Bernard Klein and Martin Villalba. As a specialist in hematology, immunology and oncology, he has built his scientific career within INSERM at Montpellier and in the US (Arizona Cancer Center and NCI). After five years at the Centre for the Fight against Cancer in Montpellier, he was in charge of the Department of Clinical Hematology and the Centre of Adult-Pediatrics Transplant Hematology of the University Hospital of Montpellier. His work concerns the discovery of new therapeutic targets, particularly in B-cell malignancies, with recognized expertise in the field of early proof of concept testing, including the search for biomarkers of interest and clinical development of drugs and new cell-drug therapy in the field of immune therapy. Moreover, he participates to an EEC network (CliNK and a new European project). Nationally, he is also involved in the field of clinical research within the cooperative groups in hematology. Finally, he acts as a consultant in pharmaceutical companies and participates in the development of a platform for clinical trials in China as an associate professor.